Skip to main content

Solid Biosciences Inc. (SLDB)

NASDAQ: SLDB · Delayed Price · USD
1.88
-0.18 (-8.54%)
At close: Nov 26, 2021 1:00 PM
1.91
0.03 (1.87%)
After-hours:Nov 26, 2021 4:28 PM EST
Market Cap206.81M
Revenue (ttm)10.47M
Net Income (ttm)-74.94M
Shares Out110.30M
EPS (ttm)-0.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,157,616
Open2.11
Previous Close2.05
Day's Range1.85 - 2.03
52-Week Range1.82 - 11.58
Beta0.88
AnalystsHold
Price Target9.58 (+410.9%)
Earnings DateNov 4, 2021

About SLDB

Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 prot...

IndustryBiotechnology
IPO DateJan 26, 2018
Employees70
Stock ExchangeNASDAQ
Ticker SymbolSLDB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for SLDB stock is "Hold." The 12-month stock price forecast is 9.58, which is an increase of 410.93% from the latest price.

Price Target
$9.58
(410.93% upside)
Analyst Consensus: Hold

News

Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Now

Short squeeze penny stocks to watch right now. The post Best Penny Stocks To Buy?

Other symbols:KALAPROGSDCSENS
1 week ago - PennyStocks

5 Short Squeeze Penny Stocks To Buy For Under $5 Right Now

5 short squeeze penny stocks to buy for under $5. Are they worth the risk?

Other symbols:AWHIVCREIVYGR
3 weeks ago - PennyStocks

Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Tops Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.79% and 7.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results

- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 -

3 weeks ago - GlobeNewsWire

Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development

- Draft white paper published today by the Pathway Development Consortium provides a framework for applying the accelerated approval pathway to AAV gene therapy development -

3 weeks ago - GlobeNewsWire

2 Net Current Asset Value Stocks to Consider

There are some investors who buy U.S.-listed stocks that are trading below their liquidation values because they believe they can gain a lot from these stocks after the market has reappraised the share ...

Other symbols:NXTC
4 weeks ago - GuruFocus

Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

1 month ago - GlobeNewsWire

Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

CAMBRIDGE, Mass. & COLUMBUS, Ohio--(BUSINESS WIRE)-- #genetherapy--Solid and Forge Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

1 month ago - Business Wire

7 Best Penny Stocks to Buy on the Nasdaq for October

Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.

Other symbols:ECORENDPPBTSUXINWIMI
1 month ago - InvestorPlace

Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial...

- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post admi...

1 month ago - GlobeNewsWire

Solid Biosciences Stock Gains After Duchenne Dystrophy Gene Therapy Data

Solid Biosciences Inc (NASDAQ: SLDB) reports 1.5-year functional data and patient-reported outcome measures in the ongoing IGNITE DMD Phase 1/2 trial of SGT-001.  SGT-001 is a novel adeno-associated vir...

2 months ago - Benzinga

Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital C...

2 months ago - GlobeNewsWire

Implied Volatility Surging for Solid Biosciences (SLDB) Stock Options

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

SLDB Stock Alert: Dear Solid Biosciences Investors, Mark Your Calendar for Sept. 23!

Solid Biosciences (SLDB) stock is rising higher today as investors prepare for an update from the company later this week. The post SLDB Stock Alert: Dear Solid Biosciences Investors, Mark Your Calendar...

2 months ago - InvestorPlace

Why Shares of Solid Biosciences Are Jumping Today

Shareholders are expecting to finally get good news.

2 months ago - The Motley Fool

Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Cli...

- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021 Vi...

2 months ago - GlobeNewsWire

Solid Biosciences to Participate at Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), ...

2 months ago - GlobeNewsWire

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Other symbols:MGTXQURESRPTVYGR
2 months ago - Zacks Investment Research

Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021

- Chief Operating Officer to discuss company's advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development -

3 months ago - GlobeNewsWire

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance

CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

3 months ago - GlobeNewsWire

Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance

CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

3 months ago - GlobeNewsWire

Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 5.56% and 14.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results

- Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 -

3 months ago - GlobeNewsWire

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development

CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

4 months ago - GlobeNewsWire

Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy

-Additional expertise expected to support attainment of key corporate goals-

4 months ago - GlobeNewsWire